Capital Research Global Investors Boosts Stake in Eli Lilly

Investment firm now owns over $19 billion in Eli Lilly shares

Published on Mar. 10, 2026

Got story updates? Submit your updates here. ›

Capital Research Global Investors, a major institutional investor, has increased its holdings in pharmaceutical giant Eli Lilly and Company by 20.9% during the third quarter. The firm now owns 25,088,371 shares of Eli Lilly's stock, worth approximately $19.14 billion and making up 3.6% of its portfolio.

Why it matters

Eli Lilly is one of the world's largest pharmaceutical companies, known for developing innovative drugs across a range of therapeutic areas. The significant increase in ownership by a major investor like Capital Research Global Investors signals confidence in the company's long-term growth prospects.

The details

According to a recent SEC filing, Capital Research Global Investors acquired an additional 4,332,008 shares of Eli Lilly during the third quarter, bringing its total stake to 25,088,371 shares. This represents 2.65% of Eli Lilly's outstanding shares and makes the investment firm one of the company's largest shareholders.

  • Capital Research Global Investors filed its latest 13F report with the SEC on March 10, 2026, disclosing its Q3 2025 holdings.
  • The firm increased its Eli Lilly stake by 20.9% during the third quarter of 2025.

The players

Capital Research Global Investors

A major institutional investment management firm that oversees over $2 trillion in assets.

Eli Lilly and Company

A global pharmaceutical company headquartered in Indianapolis, Indiana that develops and markets a wide range of medicines and therapies.

Got photos? Submit your photos here. ›

The takeaway

Capital Research Global Investors' substantial increase in its Eli Lilly holdings underscores the investment firm's confidence in the pharmaceutical company's long-term growth potential. This move highlights Eli Lilly's status as a leading player in the global drug market.